



SYMBIO
Client Focused. Results Driven.

Paper AS04- Bayesian Inference for Medical Device Reliability: Improving Safety and Effectiveness Assessments


Presented at PHUSE EU Connect 2025 (Hamburg, Germany)

Author: Shrutimita Pokhariyal, Symbio, Chandigarh, India

Are you a Bayesian?



Monty Hall problem



Introduction-Bayesian Reliability for Medical Devices



- Devices (implantables & injectables) often have limited failures and censored observations.
- Traditional frequentist methods struggle with small samples and no way to include prior knowledge.
- Bayesian inference blends prior clinical insight with observed data for stronger, transparent estimates.
- Improves uncertainty quantification and prediction, especially for rare adverse events.
- Handles incomplete/censored trials and leverages real-world evidence seamlessly.
- Case study on minimally invasive injectables: refined risk assessment and clearer regulatory decisions.

Net impact: more reliable safety evaluations and more efficient trial designs.

Why Bayesian inference clarifies safety & reliability when data are sparse

- Regulatory priority: reliable & safe devices across the lifecycle (incl. post-market).
- Problem: small early-stage datasets, rare/absent failures, rapidly evolving tech → weak frequentist estimates.
- Frequentist limitations: wide CIs, indeterminate results; hinder clear regulatory decisions.
- Bayesian advantage: integrate prior/historical evidence & expert knowledge with new data.
- Outputs posterior probabilities & credible intervals (e.g., $P[\text{failure rate} < \text{safety threshold}]$).
- Improves interpretability, uncertainty quantification, and prediction for device reliability.
- Paper roadmap: regulatory trends + real-world injectable case study.

Regulatory Momentum for Bayesian Methods in Devices



- US FDA Guidance (2010): formal endorsement of Bayesian designs
- Benefits cited: reduced sample sizes, adaptive methodologies, updatable analyses
- Adoption rising: 47 FDA-approved devices based on Bayesian trials by 2022
- Impact: improved efficiency & accuracy in safety/effectiveness evaluations

- **Limited Samples:** Narrow indications → few events; traditional estimates unstable
- **Frequentist Limits:** 0 failures $\Rightarrow$ 0 rate; wide/undefined CIs; censored follow-up weakens survival analyses
- **Rare Events (<1%):** Impractical N to detect; fixes (Firth/exact) can't use external evidence
- **Leverage History:** Iterative device generations → hierarchical/weighted priors borrow credible data
- **Post-Market Learning:** Bayesian updating integrates real-world evidence for adaptive decisions

Conclusion: Bayesian wins by

- (1) accounting for uncertainty,
- (2) incorporating historical data,
- (3) enabling continuous learning.

Incorporating Prior Knowledge

Why it matters

Combines prior knowledge with new data to quantify reliability/safety under real uncertainty.

Enables efficiency (fewer/shorter studies) while maintaining rigor when evidence aligns.

How it works (in one line)

Update beliefs via Bayes' theorem: $Posterior \propto Likelihood \times Prior$.

Sources of prior information

Previous clinical studies, bench/engineering tests, expert elicitation, computational models.

Historical/analog devices (e.g., earlier generation with similar materials/indications).

Design choices to keep it credible

Informative priors for key endpoints (e.g., failure rate, SAE rate).

Down-weighting/robust priors (mixture priors, power priors, or loss functions) to limit impact if new data disagree.

Commensurability checks (prior–data conflict diagnostics, effective sample size).

Pre-specified operating characteristics via simulation (type I error, power, precision).

Incorporating Prior Knowledge

Illustrative pattern (from MDIC-style examples)

Borrow historical safety data equivalent to ~10% of planned N (e.g., ~40 pts of prior weight).

If discordance emerges, dynamic down-weighting reduces prior influence.

When consistent, posterior estimates gain precision → potential sample/time savings.

Regulatory alignment

FDA supports appropriate prior incorporation when pre-specified and justified; improves estimate precision and decision confidence.

Takeaway

Use priors to **augment**, not replace, evidence—plan for robustness, verify commensurability, and simulate to demonstrate control of error and precision.

Modeling Rare Events and Small Samples

Why Bayesian here?

Posterior combines prior knowledge + sparse data to avoid misleading 'perfect reliability.'

Example: 0 failures in 50 devices

Frequentist: 0% observed; 95% upper bound $\approx$ 5–10% (e.g., $\sim$ 5.8%).

Bayesian: prior on $\sim$ 1% failure (e.g., Beta prior) + zero events $\rightarrow$ posterior near very low rates (median $\sim$ 1%, CrI $\sim$ 0.1–3%).

Example: 1 event in 50 patients (2%)

Frequentist (Clopper–Pearson): 95% CI $\approx$ 0.05%–10.6%.

Bayesian: prior Beta(2,198) ($\sim$ 1% expected) + data $\rightarrow$ posterior Beta(3,247); mean $\approx$ 1.2%, 95% CrI $\approx$ 0.3%–3.6%.

Predictive planning

Directly estimate $P(\geq 1 \text{ failure in next 100 patients})$ from posterior $\rightarrow$ forward-looking risk & sample-size planning.

Handling Censored and Missing Data

Why it matters

Device trials often face censoring and missingness; Bayesian methods use all available information and propagate uncertainty.

Censoring (time-to-event)

Treat censored records via their likelihood (e.g., survival to censoring time).

Specify priors on survival model parameters (e.g., Weibull shape/scale); all data contribute to the posterior.

Naturally extends to right/left/interval censoring and competing risks with hierarchical models.

Missing data (beyond ad hoc fixes)

Integrates over unknowns via posterior sampling (data augmentation), not case deletion or one-off imputations.

Reflects added uncertainty in final estimates; supports MAR/MNAR sensitivity via selection/pattern-mixture priors.

Regulatory alignment

FDA highlights Bayesian flexibility for missing data; pre-specify models, diagnostics, and sensitivity analyses.

Takeaway

Model censoring within the likelihood, integrate missing values in the posterior, and pre-plan sensitivity to ensure transparent, robust inference.

Adaptive and Hierarchical Designs

Why Bayesian for adaptives

Likelihood Principle → interim looks without multiplicity penalties when decisions use posterior probabilities.
Supports early stop for efficacy/futility, sample-size re-estimation, and dropping underperforming arms.
Operating characteristics (type I error, power, expected N) validated via simulation and pre-specification.

Decision rules (examples)

Stop for efficacy if $P(\text{effect} > \delta \mid \text{data}) \geq 0.975$; stop for futility if ≤ 0.10 .

Adaptive randomization or arm pruning based on posterior predictive success probability.

Hierarchical borrowing (partial pooling)

Assume exchangeability; estimates shrink toward aggregate when consistent, down-weight when inconsistent.

Implement via hierarchical models, commensurate priors, or power priors with dynamic weights.

Example: integrate EU experience with U.S. trial

If populations align, posterior tightens (higher precision); if not, the model reduces external weight automatically.

FDA has accepted hierarchical Bayesian approaches (e.g., borrowing adult data to inform pediatric analyses).

Takeaway

Pre-specify posterior-based rules + simulations; use hierarchical models to borrow efficiently yet robustly.

Bayesian methods address key challenges inherent to medical device trials:

- Borrowing prior information to enhance efficiency.
- Robust rare-event modeling in small datasets.
- Principled handling of censored or missing data.
- Implementation of adaptive and hierarchical designs to improve trial flexibility and relevance.

Together, these features provide a rigorous yet efficient framework that enables more precise estimates, more ethical study designs, and more confident regulatory decision-making.

Discussion of Examples and Case Study

- 1) Bayesian Approaches in Cosmetic Injectables
- 2) Wound Healing Device

Why Bayesian for devices (injectables & wound-care)

Small datasets, heterogeneity, sparse events, censored follow-up → need decision-focused outputs.

Posterior probabilities, credible intervals, predictive probabilities > binary p-values.

Principled prior use: earlier generations, historical controls, bench tests, real-world evidence.

Four regulatory-ready pillars

Smaller N when priors are credible, pre-specified, and robust (power/commensurate/mixture priors).

Adaptive features: early stop (efficacy/futility), response-adaptive randomization, N re-estimation, arm dropping.

Transparent handling of censoring/missing: model censoring in likelihood; integrate unknowns in posterior.

Hierarchical borrowing: integrate external data; auto down-weight discordant sources to preserve rigor.

Plan for priors, then test them (document basis; quantify ESS; pre-specify conflict rules).

Model what matters: align endpoints with decisions; report $P(\text{effect} \geq \text{clinically relevant margin} \mid \text{data})$.

Simulate early/often: demonstrate error control, precision, and robustness; sensitivity for missingness/fit.

Leverage continuous learning: extend to post-market surveillance with ongoing posterior updates.

Core shift

From “Is it significant?” → “How likely is a **clinically meaningful** benefit or risk—and **how large?**”

Why it matters

- Faster, more ethical trials: posterior-based early stopping; adaptive randomization
- Sharper certainty: handles rare events & censored outcomes with credible intervals
- Stronger decisions: clear probabilities at approval and post-market

What Bayesian adds

- Integrates prior evidence: historical data, bench tests, expert elicitation
- Quantifies uncertainty rigorously: credible & predictive probabilities
- Updates as data accrue: continuous learning across the device life cycle

Practical impact

- Sponsors: smaller N when priors are commensurate; decision-focused endpoints (e.g., $P(\text{effect} \geq \text{margin} \mid \text{data})$)
- Regulators: clearer benefit–risk via probabilistic statements
- Surveillance: continuously refined safety profiles

Bottom line

A principled, flexible backbone for evaluating aesthetic & minimally invasive technologies—delivering better patient outcomes and more efficient development while improving trust in device safety and effectiveness.

THANK YOU

shruti.pokhariyal@symbioresearch.com



SYMBIO
Client Focused. Results Driven.